You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

A New Era in Migraine Prevention

  • Authors: Messoud Ashina, MD, PhD, DMSc; Rami Burstein, PhD; Zaza Katsarava, MD, PhD; Patricia Pozo-Rosich, MD, PhD
  • CPD Released: 6/25/2019
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/25/2020, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an audience of European neurologists and primary care physicians.

The goal of this activity is to improve physician awareness of the science of calcitonin gene-related peptide (CGRP) in migraine prevention, key data on monoclonal antibodies (mAbs) targeting CGRP, and clinical implications of these novel treatments.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Benefits and limitations of currently available therapies for migraine prevention 
    • Mechanism of action of novel therapies in development for migraine prevention 
    • Latest efficacy and tolerability data for episodic and chronic migraine prevention therapies 


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Moderator

  • Messoud Ashina, MD, PhD, DMSc

    Professor of Neurology
    Department of Neurology
    University of Copenhagen
    Danish Headache Center
    Neuroscience Center
    Copenhagen, Denmark

    Disclosures

    Disclosure: Messoud Ashina, MD, PhD, DMSc, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Amgen, Inc. ; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva

Panelists

  • Rami Burstein, PhD

    Professor of Anesthesia and Neuroscience
    Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Rami Burstein, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alder BioPharmaceuticals Inc; Allergan, Inc.; Automated Technologies, Inc.; Avanir Pharmaceuticals, Inc.; Depomed, Inc; Dr. Reddy's Laboratories Ltd Electrocore; Percept Pharma Services, Inc; Pernix Therapeutics; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.
    Received grants for clinical research from: Allergan, Inc.; Depomed, Inc.; Dr. Reddy's Laboratories Ltd; Myelin Repair Foundation; Strategic Science & Technologies; Teva Pharmaceuticals USA; Trigemina, Inc.

    Dr Burstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Burstein does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Zaza Katsarava, MD, PhD

    Chief, Department of Neurology
    Evangelical Hospital Unna
    Professor of Neurology
    University of Essen
    Essen, Germany

    Disclosures

    Disclosure: Zaza Katsarava, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
    Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; StreamUP; Teva
    Received grants for clinical research from: Allergan, Inc.; Novartis Pharmaceuticals Corporation

  • Patricia Pozo-Rosich, MD, PhD

    Head, Headache and Craniofacial Pain Unit
    Vall d'Hebron University Hospital
    Barcelona, Spain

    Disclosures

    Disclosure: Patricia Pozo-Rosich, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; Almirall Hermal GmbH; Amgen, Inc.; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
    Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Almirall Hermal GmbH; Chiesi Farmaceutici SpA; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Teva
    Received grants for clinical research from: Allergan, Inc.

Editor

  • Leanne Fairley, BJ Hon

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Leanne Fairley, BJ Hon, has disclosed no relevant financial relationships.

Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

A New Era in Migraine Prevention

processing....

 

 
 

Educational Impact Challenge

What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.

  • Print